Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
Active, not recruiting · Phase 3 · NCT04468984
Conditions: Myelofibrosis (MF)
At a glance
- Research payments reported, 2025
- $96,283
- U.S. investigators named
- 16
- Sites paid
- 16
- Planned or actual enrollment
- 330
About the trial
- Sponsor
- AbbVie
- Tested
- Navitoclax (drug), Ruxolitinib (drug), Best Available Therapy (BAT) (drug)
- Dates
- Started 2020-08-31; completion 2026-12
- Results posted
- Not yet
Myelofibrosis (MF) is a rare blood cancer, notable for scarring of the bone marrow (the spongy tissue inside bones) and the spleen becoming larger. The purpose of this study is to assess safety and change in spleen volume when navitoclax is given in combination with ruxolitinib, compared to best available therapy, for adult participants with MF. Navitoclax is an investigational drug (not yet approved) being developed for the treatment of MF. Participants in this study will be randomly selected (like picking numbers out of a hat) to be in 1 of 2 treatment arms. Neither participants nor the study doctor will be able to pick which treatment arm a participants enters. In Arm A, participants w…
From ClinicalTrials.gov, last updated 2026-01-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $96,283 in research payments for this study in 2025 (31 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jorge E. Cortes, M.D. Hematology & Oncology · Birmingham, AL
- J T. Beck, M.D., F.A.C.P. Hematology & Oncology · Springdale, AR
- Milan R. Sheth, MD Hematology & Oncology · Long Beach, CA
- Andrew W. Pippas, MD Medical Oncology · Columbus, GA
- Jacqueline Garcia, M.D. Hematology & Oncology · Boston, MA
- Cheryl A. Sadow, MD Radiology · Boston, MA
- Vikram A. Sahni, M.D. Radiology · Wellesley, MA
- Nisha I. Sainani, M.D. Radiology · Boston, MA
- Ralph V. Boccia, M.D. Hematology & Oncology · Bethesda, MD
- Kristen M. Pettit, M.D. Hematology · Ann Arbor, MI
- James K. Mccloskey II, M.D. Medical Oncology · Hackensack, NJ
- Raajit Rampal, MD Medical Oncology · New York, NY
- William Tse, MD Medical Oncology · Cleveland, OH
- Mitul Gandhi, M.D. Hematology & Oncology · Manassas, VA
- Sri J. Obulareddy, M.D. Medical Oncology · Yakima, WA
- Anthony J. Jaslowski, M.D. Hematology & Oncology · Green Bay, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana Farbermass General Brigham $25,885
- Memorial Sloan-Kettering Cancer Ctr $14,778
- University of Michigan Health System, MI $10,750
- Virginia Cancer Specialists PC $9,150
- Hackensack University Medical Center, NJ $8,327
- $6,313
- Yakima Valley Memorial, WA $4,951
- St Vincent Hospital, WI $4,550
- Memorial Health Services $3,595
- Augusta University Research Institute Inc $2,500
- Columbus Regional Research Institute LLC $2,000
- Metrohealth System, OH $1,100
- Vx3 Imaging PC $675
- American Oncology PArtners PA $634
- Peritus Imaging Inc $450
- Highlands Oncology Group PA $326
- Ns Imaging Related Services Inc $300
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.